PharmaEngine (4162 TWO) stock market data APIs
NT$67.879
1.54(2.3%)
as of October 28, 2025
Try our APIs with
free plan!
PharmaEngine Financial Data Overview
Price chart is built with
Anychart
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Prev. Close
67.879
Open
69.4239
High
69.4239
Low
67.879
52 wk Range
63.9-113.5385
Market Cap
9 677 M
P/E Ratio
6.0282
Shares Outstanding
142 M
Revenue
2 481 M
Dividends (Yield)
0.0875
Beta
0.218
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PharmaEngine (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PharmaEngine data using free add-ons & libraries
Get PharmaEngine Fundamental Data
PharmaEngine Fundamental data includes:
- Net Revenue: 2 481 M
- EBITDA: 2 031 M
- Earnings Per Share: 11
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PharmaEngine News
New
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collabora...
Nanobiotix, PharmaEngine Terminate Development Pact For Radiation Therapy In APAC Region
Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to furth...
Nanobiotix, PharmaEngine Terminate Development Pact For Radiation Therapy In APAC Region
Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to furth...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
